Companies in health economics and policy research, 2023–2025
Companies whose researchers publish in the 14 tracked health economics and policy journals, ranked by their papers in each year from 2023 to 2025, and how much of the research has corporate authors. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.
By category: Finance · Accounting · Economics · Health Economics and Policy · Management · Marketing · Information Systems · Tourism and Hospitality · Higher Education and Research · Operations Research · Statistics · AI
Key findings#
- Of the 4,061 papers the 14 tracked health economics and policy journals published in 2023–2025, 304 (7%) have at least one author at a company; 69% of those also have a university author.
- The corporate share of health economics and policy papers went from 6% in 2017 to 7% in 2025.
- Bristol-Myers Squibb (United States) took part in the most papers (18), followed by Bristol-Myers Squibb (United Kingdom) (13) and F. Hoffmann-La Roche AG (13).
Companies#
| # | Company | Country | 2023 | 2024 | 2025 | 2023–2025 |
|---|---|---|---|---|---|---|
| 1 | Bristol-Myers Squibb (United States) | United States | 5 | 9 | 4 | 18 |
| 2 | Bristol-Myers Squibb (United Kingdom) | United Kingdom | 3 | 7 | 3 | 13 |
| 3 | F. Hoffmann-La Roche AG | Switzerland | 4 | 6 | 3 | 13 |
| 4 | Pfizer (United States) | United States | 4 | 6 | 3 | 13 |
| 5 | Health Economics and Outcomes Research (United Kingdom) | United Kingdom | 3 | 4 | 4 | 11 |
| 6 | Merck & Co., Inc., Rahway, NJ, USA (United States) | United States | 3 | 3 | 5 | 11 |
| 7 | Kleijnen Systematic Reviews (United Kingdom) | United Kingdom | 5 | 2 | 3 | 10 |
| 8 | GlaxoSmithKline (Belgium) | Belgium | 2 | 5 | 2 | 9 |
| 9 | Analysis Group (United States) | United States | 3 | 3 | 2 | 8 |
| 10 | AstraZeneca (United Kingdom) | United Kingdom | 3 | 3 | 2 | 8 |
| 11 | Novartis (Switzerland) | Switzerland | 3 | 3 | 2 | 8 |
| 12 | Pfizer (United Kingdom) | United Kingdom | 3 | 3 | 1 | 7 |
| 13 | Genentech | United States | 1 | 3 | 2 | 6 |
| 14 | Gilead Sciences (United States) | United States | 1 | 1 | 4 | 6 |
| 15 | Janssen Scientific Affairs (United States) | United States | 2 | 3 | 1 | 6 |
| 16 | GlaxoSmithKline (United Kingdom) | United Kingdom | 2 | 2 | 1 | 5 |
| 17 | Health Services Research Center (Cyprus) | Cyprus | 0 | 2 | 3 | 5 |
| 18 | Pharmacoeconomics and Health Outcomes Research Iberia (Spain) | Spain | 2 | 1 | 2 | 5 |
| 19 | Sanofi (France) | France | 0 | 3 | 2 | 5 |
| 20 | Syreon Research Institute (Hungary) | Hungary | 1 | 1 | 3 | 5 |
| 21 | AstraZeneca (Sweden) | Sweden | 2 | 0 | 2 | 4 |
| 22 | GlaxoSmithKline (United States) | United States | 1 | 1 | 2 | 4 |
| 23 | IQVIA (United Kingdom) | United Kingdom | 1 | 2 | 1 | 4 |
| 24 | Pfizer (Spain) | Spain | 0 | 1 | 3 | 4 |
| 25 | Techniker Krankenkasse (Germany) | Germany | 1 | 1 | 2 | 4 |
| 26 | Adelphi Group (United Kingdom) | United Kingdom | 0 | 0 | 3 | 3 |
| 27 | Edwards Lifesciences (Switzerland) | Switzerland | 0 | 1 | 2 | 3 |
| 28 | Ferring Pharmaceuticals (Denmark) | Denmark | 3 | 0 | 0 | 3 |
| 29 | Novartis (India) | India | 2 | 1 | 0 | 3 |
| 30 | Novo Nordisk (Denmark) | Denmark | 1 | 0 | 2 | 3 |
| 31 | Pfizer (Germany) | Germany | 1 | 1 | 1 | 3 |
| 32 | ReCor Medical (United States) | United States | 0 | 2 | 1 | 3 |
| 33 | Sciensano (Belgium) | Belgium | 0 | 1 | 2 | 3 |
| 34 | Takeda (Japan) | Japan | 1 | 1 | 1 | 3 |
| 35 | AbbVie (United States) | United States | 1 | 0 | 1 | 2 |
| 36 | Bristol-Myers Squibb (France) | France | 0 | 1 | 1 | 2 |
| 37 | CSL (United States) | United States | 1 | 0 | 1 | 2 |
| 38 | Janssen (Belgium) | Belgium | 0 | 0 | 2 | 2 |
| 39 | Johnson & Johnson (United States) | United States | 1 | 1 | 0 | 2 |
| 40 | Lundbeck (Denmark) | Denmark | 0 | 1 | 1 | 2 |
| 41 | MSD (Switzerland) | Switzerland | 2 | 0 | 0 | 2 |
| 42 | MSD (UK) Limited (United Kingdom) | United Kingdom | 1 | 1 | 0 | 2 |
| 43 | Medtronic (Ireland) | Ireland | 1 | 1 | 0 | 2 |
| 44 | Medtronic (United Kingdom) | United Kingdom | 0 | 2 | 0 | 2 |
| 45 | Otsuka (Japan) | Japan | 1 | 1 | 0 | 2 |
| 46 | PAREXEL International (United Kingdom) | United Kingdom | 2 | 0 | 0 | 2 |
| 47 | Roche (United Kingdom) | United Kingdom | 1 | 1 | 0 | 2 |
| 48 | Sanofi (Spain) | Spain | 0 | 1 | 1 | 2 |
| 49 | Takeda (Italy) | Italy | 0 | 1 | 1 | 2 |
| 50 | Vifor Pharma (Switzerland) | Switzerland | 1 | 1 | 0 | 2 |
By year#
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---|---|---|---|---|---|---|---|---|
| 6% | 8% | 8% | 8% | 9% | 9% | 8% | 7% | 7% | 6% |
Cite this page
Scholar4AI. (2026). Companies in health economics and policy research, 2023–2025. Journal Research Rankings. Retrieved October 31, 2026, from https://scholar4ai.com/rankings/companies/health-economics-and-policy
@misc{scholar4ai-rankings-companies-health-economics-and-policy,
author = {{Scholar4AI}},
title = {Companies in health economics and policy research, 2023–2025},
year = {2026},
howpublished = {\url{https://scholar4ai.com/rankings/companies/health-economics-and-policy}},
urldate = {2026-10-31},
note = {Journal Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}